These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 35861550)

  • 41. Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2.
    Song W; Gui M; Wang X; Xiang Y
    PLoS Pathog; 2018 Aug; 14(8):e1007236. PubMed ID: 30102747
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Potential use of the S-protein-Angiotensin converting enzyme 2 binding pathway in the treatment of coronavirus disease 2019.
    Feng L; Fu S; Zhang P; Zhang Y; Zhao Y; Yao Y; Luo L; Ping P
    Front Public Health; 2022; 10():1050034. PubMed ID: 36518573
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Discovery of a Putative Allosteric Site in the SARS-CoV-2 Spike Protein Using an Integrated Structural/Dynamic Approach.
    Di Paola L; Hadi-Alijanvand H; Song X; Hu G; Giuliani A
    J Proteome Res; 2020 Nov; 19(11):4576-4586. PubMed ID: 32551648
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Geraniin Inhibits the Entry of SARS-CoV-2 by Blocking the Interaction between Spike Protein RBD and Human ACE2 Receptor.
    Kim YS; Chung HS; Noh SG; Lee B; Chung HY; Choi JG
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445310
    [TBL] [Abstract][Full Text] [Related]  

  • 45.
    Br B; Damle H; Ganju S; Damle L
    F1000Res; 2020; 9():663. PubMed ID: 32765844
    [No Abstract]   [Full Text] [Related]  

  • 46. Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).
    Xiang Y; Wang M; Chen H; Chen L
    Biochem Pharmacol; 2021 Oct; 192():114724. PubMed ID: 34371003
    [TBL] [Abstract][Full Text] [Related]  

  • 47. "Molecular Masks" for ACE2 to Effectively and Safely Block SARS-CoV-2 Virus Entry.
    Shukla SP; Cho KB; Rustagi V; Gao X; Fu X; Zhang SX; Guo B; Udugamasooriya DG
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445669
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tinocordiside from
    Balkrishna A; Pokhrel S; Varshney A
    Comb Chem High Throughput Screen; 2021; 24(10):1795-1802. PubMed ID: 33172372
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Kobophenol A Inhibits Binding of Host ACE2 Receptor with Spike RBD Domain of SARS-CoV-2, a Lead Compound for Blocking COVID-19.
    Gangadevi S; Badavath VN; Thakur A; Yin N; De Jonghe S; Acevedo O; Jochmans D; Leyssen P; Wang K; Neyts J; Yujie T; Blum G
    J Phys Chem Lett; 2021 Feb; 12(7):1793-1802. PubMed ID: 33577324
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An
    Stalin A; Lin D; Senthamarai Kannan B; Feng Y; Wang Y; Zhao W; Ignacimuthu S; Wei DQ; Chen Y
    J Biomol Struct Dyn; 2022 Oct; 40(16):7408-7423. PubMed ID: 33685364
    [TBL] [Abstract][Full Text] [Related]  

  • 51.
    Tiwari V
    Biol Open; 2020 Oct; 9(10):. PubMed ID: 32878881
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targeting the viral-entry facilitators of SARS-CoV-2 as a therapeutic strategy in COVID-19.
    Muralidar S; Gopal G; Visaga Ambi S
    J Med Virol; 2021 Sep; 93(9):5260-5276. PubMed ID: 33851732
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Angiotensin-converting enzyme 2 (ACE2) receptor and SARS-CoV-2: Potential therapeutic targeting.
    Sharifkashani S; Bafrani MA; Khaboushan AS; Pirzadeh M; Kheirandish A; Yavarpour Bali H; Hessami A; Saghazadeh A; Rezaei N
    Eur J Pharmacol; 2020 Oct; 884():173455. PubMed ID: 32745604
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bergamottin and PAP-1 Induced ACE2 Degradation to Alleviate Infection of SARS-CoV-2.
    Li M; Zhang Y; Zeb A; Wu Y; Cheng L
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293419
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries.
    David AB; Diamant E; Dor E; Barnea A; Natan N; Levin L; Chapman S; Mimran LC; Epstein E; Zichel R; Torgeman A
    Molecules; 2021 May; 26(11):. PubMed ID: 34072087
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification of natural compounds as SARS-CoV-2 entry inhibitors by molecular docking-based virtual screening with bio-layer interferometry.
    Zhang D; Hamdoun S; Chen R; Yang L; Ip CK; Qu Y; Li R; Jiang H; Yang Z; Chung SK; Liu L; Wong VKW
    Pharmacol Res; 2021 Oct; 172():105820. PubMed ID: 34403732
    [TBL] [Abstract][Full Text] [Related]  

  • 57. ACE2, B
    Zhang Y; Yan R; Zhou Q
    Curr Opin Struct Biol; 2022 Jun; 74():102388. PubMed ID: 35584583
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor.
    Yang J; Petitjean SJL; Koehler M; Zhang Q; Dumitru AC; Chen W; Derclaye S; Vincent SP; Soumillion P; Alsteens D
    Nat Commun; 2020 Sep; 11(1):4541. PubMed ID: 32917884
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Luteolin inhibits spike protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) binding to angiotensin-converting enzyme 2.
    Zhu J; Yan H; Shi M; Zhang M; Lu J; Wang J; Chen L; Wang Y; Li L; Miao L; Zhang H
    Phytother Res; 2023 Aug; 37(8):3508-3521. PubMed ID: 37166054
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity.
    Essalmani R; Jain J; Susan-Resiga D; Andréo U; Evagelidis A; Derbali RM; Huynh DN; Dallaire F; Laporte M; Delpal A; Sutto-Ortiz P; Coutard B; Mapa C; Wilcoxen K; Decroly E; Nq Pham T; Cohen ÉA; Seidah NG
    J Virol; 2022 Apr; 96(8):e0012822. PubMed ID: 35343766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.